Trial Profile
Sequential Triple Therapy With Ibrutinib, Obinutuzumab and Venetoclax in First and Second Line for Patients With Chronic Lymphocytic Leukemia
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 04 Nov 2021
Price :
$35
*
At a glance
- Drugs Ibrutinib (Primary) ; Obinutuzumab (Primary) ; Venetoclax (Primary)
- Indications Chronic lymphocytic leukaemia
- Focus Therapeutic Use
- 01 Feb 2021 Status changed from recruiting to completed.
- 24 Apr 2019 Status changed from not yet recruiting to recruiting.
- 05 Dec 2018 New trial record